| 0.07475 -0.005 (-6.68%) | 03-04 14:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.1 |
1-year : | 0.12 |
| Resists | First : | 0.09 |
Second : | 0.1 |
| Pivot price | 0.08 |
|||
| Supports | First : | 0.06 | Second : | 0.05 |
| MAs | MA(5) : | 0.08 |
MA(20) : | 0.08 |
| MA(100) : | 0.14 |
MA(250) : | 0.32 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 24.2 |
D(3) : | 29.4 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 1.3 | Low : | 0.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BLCM ] has closed above bottom band by 14.9%. Bollinger Bands are 74.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 46 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.09 - 0.09 | 0.09 - 0.09 |
| Low: | 0.07 - 0.07 | 0.07 - 0.07 |
| Close: | 0.07 - 0.07 | 0.07 - 0.08 |
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
Mon, 15 Apr 2024
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates - Yahoo Movies UK
Sat, 24 Feb 2024
Bellicum Pharmaceuticals Appoints New CEO During Dissolution - TipRanks.com - TipRanks
Thu, 22 Feb 2024
Bellicum sells assets to MD Anderson, moves towards liquidation (OTCMKTS:BLCM) - Seeking Alpha
Wed, 21 Feb 2024
Bellicum Pharmaceuticals Finalizes Sale and Approves Dissolution - TipRanks.com - TipRanks
Wed, 31 Jan 2024
Bellicum Pharmaceuticals Asset Sale and Dissolution Vote Adjourned - TipRanks.com - TipRanks
Mon, 08 May 2023
Why Is Bellicum Pharmaceuticals (BLCM) Stock Up 75% Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 32.9 (%) |
| Shares Short | 1,440 (K) |
| Shares Short P.Month | 91 (K) |
| EPS | -0.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.78 |
| Profit Margin | 0 % |
| Operating Margin | -77.5 % |
| Return on Assets (ttm) | -78.1 % |
| Return on Equity (ttm) | -148.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -2.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | -0.03 |
| Price to Sales | 0.48 |
| Price to Cash Flow | -0.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|